Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7227372 | 0.93 | ESR1 (0.38) | ESR1 | |
| SCHEMBL6940319 | 0.93 | ESR1 (0.33) | ESR1 | |
| SCHEMBL7087556 | 0.93 | ESR1 (0.33) | ESR1 | |
| SCHEMBL5856061 | 0.91 | ESR1 (0.40) | ESR1 | |
| SCHEMBL5854915 | 0.91 | ESR1 (0.40) | ESR1 | |
| SCHEMBL7119390 | 0.90 | ESR1 (0.39) | ESR1ALOX15EPHX2PPARG | |
| SCHEMBL7120034 | 0.90 | — | — | |
| SCHEMBL7120032 | 0.90 | — | — | |
| SCHEMBL7237531 | 0.89 | ALDH1A1 (0.31) | ALDH1A1TSHRMAPK1TDP1L3MBTL1 | |
| SCHEMBL5854225 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHRL3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610733-B2 | Antiestrogen, therapeutic agent for breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1241165-A1 | OPTICALLY ACTIVE CHROMAN AND THIOCHROMAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125571-A1 | Optically active chroman and thiochroman derivatives | NR5A1, CYP19A1, SHBG | ESR1 8/4885ALDH1A1 762/4885TSHR 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.